Melissa Epperly
About Melissa Epperly
Current Role as Director
Melissa Epperly currently holds the position of Director. Her extensive background in financial leadership, particularly within the pharmaceutical industry, positions her uniquely for this role. She leverages her experience to oversee and guide financial strategies, ensuring that the company's objectives align seamlessly with its long-term goals.
Chief Financial Officer at Zentalis Pharmaceuticals
From September 2019 to April 2024, Melissa Epperly served as the Chief Financial Officer at Zentalis Pharmaceuticals, Inc. In this role, she was responsible for overseeing the company's financial strategy, managing financial risks, and ensuring stable economic growth. Her tenure saw crucial financial decisions that helped shape the company's direction and stability.
Chief Financial Officer at PsiOxus Therapeutics
Melissa Epperly served as the Chief Financial Officer at PsiOxus Therapeutics Ltd. from June 2018 to August 2019. PsiOxus Therapeutics is a clinical-stage gene therapy company focused on cancer treatment. During her term, she managed financial operations and spearheaded initiatives to support the company's clinical development pipeline.
Chief Financial Officer at R-Pharm US
From October 2015 to June 2018, Melissa Epperly held the dual roles of Chief Financial Officer and Head of Business Development at R-Pharm US. As a commercial-stage oncology company, R-Pharm US benefited from her expertise in both finance and business development, enabling strategic expansions and financial planning integral to the company's growth.
Director at Anchorage Capital Group
Melissa Epperly was a Director at Anchorage Capital Group from August 2012 to September 2015. During her time at this credit-focused hedge fund, she played a significant role in financial analysis, investment strategies, and managing credit-focused portfolios. Her work contributed to the fund's performance and strategic direction.
Educational Background
Melissa Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia. Additionally, she earned an M.B.A from Harvard Business School. Her academic background provides a strong foundation in both scientific and business disciplines, supporting her comprehensive approach to financial leadership in the pharmaceutical industry.